Zacks Investment Research upgraded shares of INVO Bioscience (NASDAQ:INVO – Get Rating) from a hold rating to a buy rating in a research report released on Friday, Zacks.com reports. The firm currently has $2.25 target price on the stock.
According to Zacks, “INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East. “
A number of other equities research analysts have also recently commented on INVO. Maxim Group assumed coverage on INVO Bioscience in a research note on Wednesday, January 19th. They issued a buy rating and a $7.00 price target for the company. Roth Capital cut INVO Bioscience from a buy rating to a neutral rating and decreased their price target for the company from $4.00 to $2.00 in a research note on Wednesday. Finally, Colliers Securities reiterated a buy rating on shares of INVO Bioscience in a research note on Tuesday, March 22nd.
Large investors have recently made changes to their positions in the company. Magnus Financial Group LLC purchased a new position in shares of INVO Bioscience in the fourth quarter worth about $33,000. Eidelman Virant Capital purchased a new position in shares of INVO Bioscience in the first quarter worth about $29,000. Susquehanna International Group LLP purchased a new position in shares of INVO Bioscience in the fourth quarter worth about $46,000. Finally, Connors Investor Services Inc. raised its stake in shares of INVO Bioscience by 27.3% in the fourth quarter. Connors Investor Services Inc. now owns 49,000 shares of the company’s stock worth $163,000 after purchasing an additional 10,500 shares during the last quarter. Hedge funds and other institutional investors own 14.80% of the company’s stock.
INVO Bioscience Company Profile (Get Rating)
INVO Bioscience, Inc, a medical device company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a patented intravaginal culture system used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. The company was founded in 2007 and is based in Sarasota, Massachusetts.
- Get a free copy of the StockNews.com research report on INVO Bioscience (INVO)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- UiPath Stock is Nearing Rock Bottom Down Here
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.